Eka Aryani 22010112110093 Lap KTI BAB 7

(1)

DAFTAR PUSTAKA

1. Creager M, Libby P. Peripheral Arterial Disease In: Mann DL, Zipes DP, Libby P, Bonow RO, editors. Braunwald’s Heart Disease : A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier Saunders; 2015. 1312 p.

2. Antono D, Hamonangani R. Penyakit Arteri Perifer. In: Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 1516–26.

3. Rhee SY, Kim YS. Peripheral Arterial Disease in Patients with Type 2 Diabetes Mellitus. 2015;283–90.

4. Coffman JD, Eberhardt RT. Peripheral Arterial Disease, Diagnosis and Treatment. New York: Springer Seienee&Business Media; 2003.1-34p. 5. Rooke TW, Hirsch a. T, Misra S, Sidawy a. N, Beckman J a., Findeiss LK,

et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease. Circulation. Elsevier Inc.; 2011;58(19):2020–45.

6. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. Elsevier Ltd; 2013;382(9901):1329–40.

7. Selvin E. Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.

8. Fowkes FGR, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: Results of the international AGATHA study. Eur Heart J. 2006;27(15):1861–7.

9. Rhee SY, H G, ZM L, SW-K C, S W, P P. Multi-country study on the prevalence and clinical features of peripheral arterial disease in Asian type 2 diabetes patients at high risk of atherosclerosis. Diabetes Res Clin Pract. 2007;76(1):82–92.

(2)

11. American Heart Association. What is peripheral vascular disease? In American Heart Association; 2012.

12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation. 2006;113(11):e463–5.

13. Norgren L, Hiatt WR, Dormandy J a., Nehler MR, Harris K a., Fowkes FGR, et al. Inter-Society Consensus for the management of peripheral arterial disease (TASC II). Int Angiol. 2007;26(2):82–157.

14. F Brian Boudi M. Coronary Artery Atherosclerosis Treatment & Management. Medscape. 2016; [cited 2016 Jun 17]

15. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921–9.

16. The Japan Diabetes Society. Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013. Diabet Med. 2013;1–3.

17. Ilmiah Populer [Internet]. [cited 2016 Jan 26]. Available from: http://www.pdpersi.co.id/content/popular_science.php?psid=30

18. Dinas Kesehatan Jateng. Daftar Tabel Profil Kesehatan Provinsi Jawa Tengah. Semarang: Dinkes Jateng; 2008. 38 p.

19. Huh JH, Choi E, Lim JS, Lee MY, Chung CH, Shin JY. Serum cystatin C levels are associated with asymptomatic peripheral arterial disease in type 2 diabetes mellitus patients without overt nephropathy. Diabetes Res Clin Pract. Elsevier Ireland Ltd; 2015;108(2):258–64.

20. Rahman A. Faktor – Faktor Risiko Mayor Aterosklerosis pada Berbagai Penyakit Aterosklerosis di RSUP Dr. Kariadi Semarang. Diponegoro University; 2012.

21. Tomeleri CM, Ronque ER, Silva DR, Cardoso Junior CG, Fernandes R a, Teixeira DC, et al. Prevalence of dyslipidemia in adolescents: comparison between definitions. Rev Port Cardiol. Sociedade Portuguesa de Cardiologia; 2015;34(2):103–9.

22. Bittner V. Perspectives on dyslipidemia and coronary heart disease in women: an update. Curr Opin Cardiol. 2006;21(6):602–7.

(3)

24. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS) 2007. Lap Nas 2007. 2008;1–384.

25. Rinandyta SA. Perbedaan Kadar LDL pada Penderita Diabetes Melitus Tipe 2 dengan Hipertensi dan Tanpa Hipertensi di RSUD Dr. Moewardi. Universitas Muhammadiyah Surakarta; 2012.

26. Ilminovia F. Hubungan antara Status Diabetes Melitus dengan Status Penyakit Arteri Perifer (PAP) pada Pasien Hipertensi In Abstract Book ESC 26th. European student congress; 2015.

27. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 18th ed. New York: Mc Graw Hill; 2012. 2066 p.

28. Agrawal K, Eberhardt RT. Contemporary Medical Management of Peripheral Arterial Disease. Cardiol Clin. Elsevier Inc; 2015;33(1):111–37. 29. Runge MS, Greganti MA. Netter’s Internal Medicine. 2nd ed. Philadelphia:

Saunders Elsevier; 2009. 213 p.

30. McDermott, M M, McGrae. Lower Extremity Manifestations of Peripheral Artery Disease. Am Hear Assoc J. 2015;115:1540–50.

31. Lozano FS, González-Porras JR, March JR, Lobos JM, Carrasco E, Ros E. Diabetes mellitus and intermittent claudication: a cross-sectional study of 920 claudicants. Diabetol Metab Syndr. 2014;6:21.

32. Hallett Jr JW. Peripheral Arterial Disease. Merck Manuals. 2008;169–73. 33. Bordeaux LM, Reich LM, Hirsch AT. The Epidemiology and Natural.

Springer J. 2003;(Ic):21–35.

34. Baker. Smoking and Peripheral Arterial Disease ( PAD ). ASH Research Report Smoking and Peripheral Arterial Disease. 2014;

35. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, Collet J-P, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treat. Eur Heart J. 2011;32(22):2851–906.

(4)

37. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG. Peripheral arterial disease detection, awarness and treatment in primary care. JAMA. 2001;286(11):1317–24.

38. Age AT. Peripheral Arterial Disease in the Legs. In: CdcGov. p. 4–5. 39. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL.

ACC/AHA 2005 practice guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Sur. Circulation. 2006;113(11):463– 654.

40. Suyono S. Diabetes Melitus. In: Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2315–418.

41. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care. 2015;38(Supplement_1):S8–16.

42. Hirsch a T, Hiatt WR. PAD awareness, risk, and treatment: new resources for survival--the USA PARTNERS program. Vasc Med. 2001;6(3 Suppl):9–12.

43. Joshua A, Beckman, MD M, Mark A. Creager M, Peter Libby M. Diabetes and Atherosclerosis Epidemiologi, Pathophysiology, and Management. JAMA. 2002;(287):2570–81.

44. Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S, et al. Muscle Perfusion by Capillary Recruitment. 2001;50

45. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. European Heart Journal. 2012;33(7):829–37.

46. Hua L, Hongliang L, Yige B, Xiangxun Z, Yerong Y. Free Fatty Acids Induce Endothelial Dysfunction and Activate Protein Kinase C and Nuclear Factor-κB Pathway in Rat Aorta. Int J Cardiol. 152(2):218–24.

47. Erwinanto, Santoso A, Putranto JNE, Tedjasukmana P, Suryawan R, Rifqi S, et al. Pedoman tatalaksana dislipidemia. 1st ed. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2013.1-7p.

(5)

49. Fodor G. Primary prevention of CVD: Treating dyslipidemia. Am Fam Physician. 2011;83(10):1207–8.

50. Adam JM. Dislipidemia. In: Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2549–68.

51. Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei B, et al. Metformin beyond diabetes: Pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):1–12.

52. Jamkhande PG, Chandak PG, Dhawale SC, Barde SR, Tidke PS, Sakhare RS. Therapeutic approaches to drug targets in atherosclerosis. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. King Saud University; 2014;22(3):179– 90.

53. Elizabeth Klodas M. High Blood Pressure and Atherosclerosis. WebMD. 2016; [cited 2016 Jun 17]

54. Aboyans V, Criqui MH, Abraham P, Allison M a., Creager M a., Diehm C, et al. Measurement and Interpretation of the Ankle-Brachial Index: A Scientific Statement From the American Heart Association. Circulation. 2012;126(24):2890–909.

55. Mahameed A Al. Peripheral Arterial Disease. Cleve Clin J Med. 2009; 56. Bonham P, Cappuccio M, Hulsey T, Michel Y, Kelechi T, Jenkins C. Are

Ankle and Toe Brachial Indices (ABI-TBI) Obtained by a Pocket Doppler Interchangeable With Those Obtained by Standard Laboratory Equipment? J Wound, Ostomy Cont Nurs. 2007;34(1):35–44.

57. Carmo G a L, Mandil a, Nascimento BR, Arantes BD, Bittencourt JC, Falqueto EB, et al. Can we measure the ankle-brachial index using only a stethoscope? A pilot study. Fam Pract. 2009;26(1):22–6.

58. WOCN Wound Committee. Ankle Brachial Index. J Wound, Ostomy Cont Nurs. 2012;39(April):S21–9.

59. Inada A, Weir GC, Bonner-Weir S. Induced ICER I?? down-regulates cyclin a expression and cell proliferation in insulin-producing ?? cells. Biochem Biophys Res Commun. 2005;329(3):925–9.

60. Yogiantoro M. Hipertensi Esensial. Buku Ajar Ilmu Penyakit Dalam Jilid 1. IV. Jakarta: FKUI; 2006. 610-14 p.

(6)

62. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.

(7)

Lampiran 1. Informed Consent (Persetujuan Pasien)

JUDUL PENELITIAN : Hubungan antara Dislipidemia dengan Derajat Keparahan Penyakit Arteri Perifer (PAP) pada Pasien Diabetes Melitus Tipe 2 Terkontrol Sedang. INSTANSI PELAKSANA : Bagian Ilmu Penyakit Dalam FK Undip -

Mahasiswa Program Studi Strata-1 Kedokteran Umum Fakultas Kedokteran Universitas Diponegoro

PERSETUJUAN SETELAH PENJELASAN

(

INFORMED CONSENT)

Yth Bapak/Ibu ………..

(8)

terpilih sebagai peserta penelitian ini. Apabila Bapak/Ibu setuju untuk menjadi peserta penelitian maka ada beberapa hal yang akan Bapak/Ibu alami, yaitu:

- Pengambilan informasi nama, umur, jenis kelamin, status merokok, status hipertensi dan keluhan yang dirasakan melalui wawancara

- Diukur tekanan darah pada kedua kaki dan kedua lengan pada saat istirahat - Dan bila diperlukan, akan diukur tekanan darah pada kaki setelah berolah

raga naik-turun bangku selama 4-5 menit atau berjalan selama 6 menit atau dorsofleksi plantarfleksi selama 6 menit.

Keuntungan bagi Bapak/Ibu yang bersangkutan ikut dalam penelitian ini adalah mendapat fasilitas pendeteksian Penyakit Arteri Perifer (PAP) serta mengetahui derajat PAP yang diderita apabila terdeteksi. Dengan dilakukanya pendeteksian ini, kita dapat mengetahui apakah terdapat sumbatan pembuluh darah pada lengan atau kaki Bapak/Ibu. Bapak/Ibu juga akan diberi pemahaman mengenai PAP. Saya menjamin bahwa penelitian ini tidak akan menimbulkan efek yang merugikan pada Bapak/Ibu. Dalam penelitian ini tidak ada intervensi dalam bentuk apapun terhadap Bapak/ Ibu. Setiap data pemeriksaan dan penelitian dijamin kerahasiaannya dengan tidak mencantumkan identitas subyek. Sebagai peserta penelitian keikutsertaan ini bersifat sukarela dan tidak dikenakan biaya penelitian.

Penanggung jawab penelitian:

Eka Aryani

085642702444

Sudah mendengar dan memahami penjelasan penelitian, dengan ini saya menyatakan

SETUJU / TIDAK SETUJU

untuk ikut sebagai subyek/sampel penelitian ini.

Tegal, ……….2016

Saksi

Nama Terang : Nama Terang :

(9)

Lampiran 2

DAFTAR TILIK PENELUSURAN REKAM MEDIK

No Keterangan

Nama

Jenis Kelamin Umur

Alamat No HP

Kontrol teratur/tidak Status merokok ya/ tidak DM

Status glikemik (HbA1c): Kadar gula darah terakhir GDS:

GDP:

Lamanya DM: Obat yang diminum: Dislipidemia ya/ tidak TC:

LDL: HDL: TG:

Lamanya dislipidemia: Obat yang diminum: Hipertensi

(10)

Lampiran 3

LEMBAR PENGUMPULAN DATA

ANKLE-BRACHIAL INDEX (ABI)

Tanggal Pemeriksaan:

Nama Pasien: Umur:

Catatan:

Apakah ada aktivitas berat yang baru saja dilakukan/ konsumsi kafein/ alkohol terakhir

Jenis Kelamin:

ABI saat istirahat

Kanan Pengukuran Rata-rata

Kiri Pengukuran Rata-rata

I II I II

Brachialis Brachialis

Tibialis Posterior

Tibialis Posterior Dorsalis

Pedis

Dorsalis Pedis

ABI kanan = rata−rata tertinggi tekanan sistolik kaki kanan DP atau TP rata−rata tertinggi tekanan sistolik lengan kanan atau kiri

ABI kiri = rata−rata tertinggi tekanan sistolik kaki kiri DP atau TP rata−rata tertinggi tekanan sistolik lengan (kanan atau kiri)

(11)

ABI setelah exercise

(Diakukan apabila nilai ABI saat istirahat normal namun terdapat gejala

klaudikasio)

Lamanya exercise =

Nilai tekanan sistolik kaki setelah exercise = Nilai ABI setelah exercise =

Kelengkapan Data

Status Merokok : Lamanya DM :

Lamanya Dislipidemia

(12)

(13)

(14)

(15)

(16)

Lampiran 6. Biodata Mahasiswa

Identitas

Nama Lengkap : Eka Aryani Jenis Kelamin : Perempuan

Program Studi : Pendidikan Dokter

NIM : 22010112110093

Tempat, tanggal lahir : Tegal, 14 Februari 1995 E-mail : eka.aryani1402@gmail.com Nomor telepon/HP : 085642702444

Riwayat Pendidikan Formal

SD SMP SMA S1

Nama Institusi SDN

Margadana 3

2000-2006 2006-2009 2009-2012 2012

Organisasi yang Pernah Diikuti:

Lembaga Tahun

Divisi Pengembangan Mahasiswa Kelompok Studi Mahasiswa FK UNDIP

2013-2014

Bidang Riset HIMA KU UNDIP 2012-2014 Kelompok Ilmiah Remaja SMAN 1

Kota Tegal

2010-2012

Pengalaman Mengikuti Lomba Karya Ilmiah

(17)

Lampiran 7. Hasil SPSS

Frequencies Frequency Table

Status Dislipidemia

Frequency Percent Valid Percent Cumulative

Percent

Std. Deviation 7,250

Minimum 46

Maximum 71

Usia

(18)

64 3 10,0 10,0 66,7

Percent

Status Dislipidemia * Status PAP

(19)

Status Dislipidemia * Status PAP Crosstabulation

Continuity Correctionb 6,356 1 ,012

Likelihood Ratio 11,699 1 ,001

Fisher's Exact Test ,004 ,003

Linear-by-Linear Association 8,286 1 ,004

N of Valid Cases 30

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 3,60. b. Computed only for a 2x2 table

Risk Estimate

Value 95% Confidence Interval

Lower Upper

For cohort Status PAP = Tidak

,429 ,262 ,702

(20)

T-Test

t-test for Equality of Means

F Sig. t df Sig. (2-Interval of the

Difference

Levene's Test for Equality of Variances

(21)

T-Test

Mann-Whitney U 25,000

Wilcoxon W 70,000

Z -2,061

Asymp. Sig. (2-tailed) ,039

Exact Sig. [2*(1-tailed Sig.)] ,041b

a. Grouping Variable: Status PAP b. Not corrected for ties.

Independent Samples Test

(22)

Crosstabs

jumlah dislipidemia * Status PAP Crosstabulation

Status PAP Total

N of Valid Cases 21

(23)

Frequencies

jenis komponen

Percent

Valid

HDL 4 19,0 19,0 19,0

TG 2 9,5 9,5 28,6

TC HDL 1 4,8 4,8 33,3

HDL TG 10 47,6 47,6 81,0

LDL HDL 1 4,8 4,8 85,7

TC LDL HDL 2 9,5 9,5 95,2

TC LDL HDL TG 1 4,8 4,8 100,0

Total 21 100,0 100,0

NPar Tests

Descriptive Statistics

N Mean Std.

Deviation

Minimum Maximum Percentiles

25th 50th

(Median)

75th

jenis komponen

21 3,57 1,720 1 7 2,00 4,00 4,00

(24)

Mann-Whitney Test

Mann-Whitney U 13,500

Wilcoxon W 58,500

Z -3,059

Asymp. Sig. (2-tailed) ,002

Exact Sig. [2*(1-tailed Sig.)] ,002b

a. Grouping Variable: Status PAP b. Not corrected for ties.

Crosstabs

Jenis kelamin * Status PAP Crosstabulation

(25)

Chi-Square Tests

Continuity Correctionb ,051 1 ,821

Likelihood Ratio ,361 1 ,548

Linear-by-Linear Association ,350 1 ,554

N of Valid Cases 30

Risk Estimate

Lower Upper

Odds Ratio for Jenis kelamin (Laki-laki / Perempuan)

,636 ,145 2,784

For cohort Status PAP = Ya ,765 ,320 1,828

(26)

Crosstabs

Case Processing Summary

Cases

Valid Missing Total

N Percent N Percent N Percent

Status merokok * Status PAP

30 100,0% 0 0,0% 30 100,0%

Status merokok * Status PAP Crosstabulation

Status PAP Total

(27)

a. 6 cells (75,0%) have expected count less than 5. The minimum expected count is 1,20.

Risk Estimate

Value

Odds Ratio for Status merokok (Ya / pasif)

a

a. Risk Estimate statistics cannot be computed. They are only computed for a 2*2 table without empty cells.

Crosstabs

Hipertensi * Status PAP Crosstabulation

(28)

Chi-Square Tests

N of Valid Cases 30

Risk Estimate

Lower Upper

Odds Ratio for Hipertensi (Ya / Tidak)

10,500 1,889 58,359

For cohort Status PAP = Ya 3,923 1,320 11,656

Penyakit atherosclerosis lain * Status PAP

30 100,0% 0 0,0% 30 100,0%

Penyakit atherosclerosis lain * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

(29)

% within Status PAP 66,7% 83,3% 76,7%

Continuity Correctionb ,380 1 ,537

N of Valid Cases 30

Risk Estimate

Lower Upper

Odds Ratio for Penyakit atherosclerosis lain (Ya / Tidak)

2,500 ,445 14,037

For cohort Status PAP = Ya 1,643 ,701 3,849

,657 ,266 1,626

N of Valid Cases 30

Crosstabs

Minum obat * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

Minum obat Teratur

Count 6 16 22

Expected Count 8,8 13,2 22,0

% within Status PAP 50,0% 88,9% 73,3%

% of Total 20,0% 53,3% 73,3%

(30)

Expected Count 3,2 4,8 8,0

N of Valid Cases 30

Risk Estimate

Lower Upper

Odds Ratio for Minum obat (Teratur / Tidak teratur)

,125 ,020 ,799

For cohort Status PAP = Ya ,364 ,165 ,802

Obat dislipidemia * Status PAP

(31)

Obat dislipidemia * Status PAP Crosstabulation

tidak minum obat

Count 0 7 7

N of Valid Cases 30

a. 4 cells (66,7%) have expected count less than 5. The minimum expected count is 2,80.

Risk Estimate

Value

Odds Ratio for Obat dislipidemia (ya / tidak)

a

(32)

Crosstabs

obat hipertensi * Status PAP Crosstabulation

Status PAP Total

tidak minum obat

Count 3 14 17

N of Valid Cases 30

(33)

Risk Estimate

Value

Odds Ratio for obat hipertensi (teratur / tidak teratur)

a

a. Risk Estimate statistics cannot be computed. They are only computed for a 2*2 table without empty cells.

Logistic Regression

Case Processing Summary

Unweighted Casesa N Percent

Selected Cases

Included in Analysis 30 100,0

Missing Cases 0 ,0

Total 30 100,0

Unselected Cases 0 ,0

Total 30 100,0

a. If weight is in effect, see classification table for the total number of cases.

Dependent Variable Encoding

Original Value Internal Value

Ya 0

Tidak 1

Categorical Variables Codings

Frequency Parameter coding

(1)

Minum obat Teratur 22 1,000

Tidak teratur 8 ,000

Hipertensi Ya 13 1,000

Tidak 17 ,000

Block 0: Beginning Block

Classification Tablea,b

Observed Predicted

Status PAP Percentage

Correct

Ya Tidak

Step 0

Status PAP Ya 0 12 ,0

Tidak 0 18 100,0

Overall Percentage 60,0

(34)

b. The cut value is ,500

Variables in the Equation

B S.E. Wald df Sig. Exp(B)

Step 0 Constant ,405 ,373 1,184 1 ,277 1,500

Variables not in the Equation

Score df Sig.

Step 0 Variables

Hipertensi(1) 8,167 1 ,004

obat_dm(1) 5,568 1 ,018

Overall Statistics 10,027 2 ,007

Block 1: Method = Backward Stepwise (Likelihood Ratio)

Omnibus Tests of Model Coefficients

Chi-square df Sig.

a. A negative Chi-squares value indicates that the Chi-squares value has decreased from the previous step.

Model Summary

a. Estimation terminated at iteration number 4 because parameter estimates changed by less than ,001.

Hosmer and Lemeshow Test

Step Chi-square df Sig.

1 ,070 2 ,966

(35)

Contingency Table for Hosmer and Lemeshow Test

Status PAP = Ya Status PAP = Tidak Total

Observed Expected Observed Expected

Step 1

Observed Predicted

Status PAP Percentage

Correct

Ya Tidak

Step 1

Status PAP Ya 9 3 75,0

Tidak 4 14 77,8

Step 2

Status PAP Ya 9 3 75,0

Tidak 4 14 77,8

a. The cut value is ,500

Variables in the Equation

B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B)

(36)

Model if Term Removed

Variable Model Log

Likelihood

Change in -2 Log Likelihood

df Sig. of the

Change

Step 1 Hipertensi -17,390 5,190 1 ,023

obat_dm -15,946 2,303 1 ,129

Step 2 Hipertensi -20,190 8,488 1 ,004

Variables not in the Equation

Score df Sig.

Step 2a Variables obat_dm(1) 2,360 1 ,124

Overall Statistics 2,360 1 ,124